anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a natural bionic process based on a cold chain, a new product produced by the natural bionic process based on the cold chain and application. The natural bionic process comprises the steps of pretreatment, bionic extraction, separation and concentration, sterilization and drying. The application of the natural bionic technology based on the cold chain in the preparation of the biological original ecological activity essence. The invention relates to a biological essence concentrated solution, which is prepared by carrying out cold chain transportation, storage and fresh keeping on fresh organisms, breaking the walls of fresh products, quick-frozen products, freeze-dried products or dried products, or grinding the fresh products, the quick-frozen products, the freeze-dried products or the dried products into pulp at low temperature, then putting the pulp into a membrane bioreactor, extracting by taking water as a medium, and separating, removing impurities, dehydrating and concentrating an extracting solution. A closed circulating cold reflux system is formed by the membrane bioreactor, the dialysis separation device and the dehydration concentration device, and can simultaneously carry out extraction, separation and concentration. Sterilizing the concentrated solution, immediately freezing and temporarily storing, freeze-drying to obtain dried substance, and packaging into powder, tablet or capsule.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to method of synthesis of thiazolidinediones of the formula (III)   where A means CH=CH or S; W means O; X means S, O or NR 2  where residue R 2  is hydrogen atom or C 1 -C 6 -alkyl; Y means CH or N; R means naphthyl, thienyl or phenyl that is optionally substituted once or twice with C 1 -C 3 -alkyl, CF 3 , C 1 -C 3 -alkoxy-group, F, Cl or bromine atom;  R 1  means hydrogen atom, C 1 -C 6 -alkyl and n = 1-3 by reduction of compound of the formula (IV)   with metallic aluminum in protonic solvent. Invention relates to also medicinal agents containing usual additions and auxiliary substances and one of derivative of thiazolidinedione as indicated above. Derivatives of thiazolidinedione are used for preparing medicinal agents designated for treatment of patients with diabetes mellitus. EFFECT: improved method of synthesis of thiazolidinediones. 7 cl, 1 tbl, 2 ex
The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
TIPS has been used for 20 years, as a means of reducing portal pressure in patients with cirrhosis and portal hypertension related complications. TIPS proved more effective than alternative treatments in controlling or preventing variceal bleeding and refractory ascites. The main drawback of the TIPS procedure is progressive overt hepatic encephalopathy (OHE). Three risk factors for post-TIPS OHE have been identified: age over 65 years, history of previous episodes of OHE, and Child-Pugh score equal to or over 10. However, the incidence of post-TIPS OHE in patients fulfilling these criteria remains close to 35 %. Furthermore, the pathogenesis of HE in general but also in patients treated by TIPS is still not well understood. Therefore, there is a real challenge in discovering new molecular mechanisms involved in pathogenesis of OHE as well as new treatment to better prevent the risk of OHE in patients treated by TIPS. Observational and experimental studies suggest a microbiota's role in the mechanism of OHE and recently a non absorbable antibiotic has proven to reduce the risk of recurrence of OHE. However, the effect of this drug for the prevention of a first episode of OHE in patients treated by TIPS is not known. In addition, the mechanisms of the beneficial effect of rifaximin remain poorly understood.
* Initiate dosing at 2 mg orally twice daily, with or without food. 
  * Initially, titrate the dosage by 1 to 2 mg twice daily, no more frequently than every 2 weeks based on the rate of cortisol changes, individual tolerability and improvement in signs and symptoms of Cushing's disease. If a patient tolerates ISTURISA dosage of 10 mg twice daily and continues to have elevated 24-hour urine free cortisol (UFC) levels above upper normal limit, the dosage can be titrated further by 5 mg twice daily every 2 weeks. Monitor cortisol levels from at least two 24-hour urine free cortisol collections every 1-2 weeks until adequate clinical response is maintained. 
  * The maintenance dosage of ISTURISA is individualized and determined by titration based on cortisol levels and patient's signs and symptoms. 
  * The maintenance dosage varied between 2 mg and 7 mg twice daily in clinical trials. The maximum recommended maintenance dosage of ISTURISA is 30 mg twice daily. 
  * Once the maintenance dosage is achieved, monitor cortisol levels at least every 1-2 months or as indicated.
* Select patients for the treatment of metastatic NSCLC with ROZLYTREK based on the presence of ROS1 rearrangement(s) in tumor or plasma specimens [see Clinical Studies (14.1)]. Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing.  
Information on FDA-approved tests for the detection of ROS1 rearrangement(s) in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.
  * Select patients for treatment of locally advanced or metastatic solid tumors with ROZLYTREK based on the presence of a NTRK gene fusion in tumor or plasma specimens [see Clinical Studies (14.2)]. Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing.  
Information on FDA-approved tests for the detection of NTRK gene fusion(s) in solid tumors is available at http://www.fda.gov/CompanionDiagnostics.
<P>PROBLEM TO BE SOLVED: To simply emulsify or solubilize a slightly water-soluble physiologically active substance in water with good dispersion stability and to improve the touch or/and stability of a physiologically active substance in water when used for a cosmetic or an external preparation for skin depending on the kind of the slightly water-soluble physiologically active substance.  <P>SOLUTION: A slightly water-soluble physiologically active substance-phospholipid composite, obtained by removing an organic solvent from a solution in which the slightly water-soluble physiologically active substance and a phospholipid are uniformly dissolved in the organic solvent and simultaneously depositing the slightly water-soluble physiologically active substance and phospholipid, is used. Furthermore, a slightly water-soluble physiologically active substance-sterol-phospholipid composite comprising the sterol is used. The slightly water-soluble physiologically active substance can simply be emulsified or solubilized in water by using the composite. The resultant emulsified or solubilized composition has high dispersion stability. The touch when used in the cosmetic or external preparation for skin or/and stability of the physiologically active substance in water are improved depending on the kind of the physiologically active substance.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Ibuprofen, a commonly used over-the-counter medication, is widely recognized for its effective pain relief properties but is also associated with various adverse effects, including rare ocular and neurological manifestations. We report a case of a 27-year-old male who experienced transient vertical diplopia following a standard ibuprofen dosage for back pain. Symptoms resolved promptly upon discontinuation of the drug, with normal findings on extensive clinical and laboratory evaluations. The clinical presentation, suggestive of skew deviation, implies central toxicity. This case underscores the potential for diplopia associated with NSAIDs like ibuprofen to be underdiagnosed and offers valuable insights into the central toxicity of ibuprofen. Further research is warranted to elucidate the underlying mechanisms and optimize patient care in similar scenarios.
The forced rate exercise+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 revolutions per minute (RPM). Target heart rate zone will be set to 60-80% of heart rate (HR) reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
A computer-implemented method is disclosed. The method includes receiving, at a computing device, a first treatment plan designed to treat an invasive surgical-related health issue of a user. The first treatment plan comprises at least two exercise sessions that, based on the invasive surgical-related health issue, enable the user to perform an exercise at different exertion levels. Next, while the user uses the electromechanical machine to perform the first treatment plan, receiving, at the computing device, data from sensors configured to measure the data associated with the invasive surgical-related health issue and transmitting the data. One or more machine learning models are used to generate a second treatment plan. The second treatment plan modifies at least one exertion level, and the modification is based on a standardized measure comprising perceived exertion, the data, and the invasive surgical-related health issue. The method additionally includes receiving the second treatment plan.
The recommended doses of fexofenadine hydrochloride in pediatric patients 6 months to 11 years of age are based on cross-study comparison of the pharmacokinetics of fexofenadine in adults and pediatric subjects and on the safety profile of fexofenadine hydrochloride in both adult and pediatric subjects at doses equal to or higher than the recommended doses. The safety and effectiveness of fexofenadine hydrochloride in pediatric patients under 6 months of age have not been established. 

The safety of fexofenadine hydrochloride is based on the administration of fexofenadine hydrochloride tablets at a dose of 30 mg twice daily demonstrated in 438 pediatric subjects 6 years to 11 years of age in 2 placebo-controlled 2-week seasonal allergic rhinitis trials. The safety of fexofenadine hydrochloride at doses of 15 mg and 30 mg given once and twice a day has been demonstrated in 969 pediatric subjects (6 months to 5 years of age) with allergic rhinitis in 3 pharmacokinetic studies and 3 safety studies. The safety of fexofenadine hydrochloride for the treatment of chronic idiopathic urticaria in subjects 6 months to 11 years of age is based on cross-study comparison of the pharmacokinetics of fexofenadine hydrochloride in adult and pediatric subjects and on the safety profile of fexofenadine in both adult and pediatric subjects at doses equal to or higher than the recommended dose. 

The effectiveness of fexofenadine hydrochloride for the treatment of seasonal allergic rhinitis in subjects 6 to 11 years of age was demonstrated in 1 trial (n=411) in which fexofenadine hydrochloride tablets 30 mg twice daily significantly reduced total symptom scores compared to placebo, along with extrapolation of demonstrated efficacy in subjects aged 12 years and above, and the pharmacokinetic comparisons in adults and children. The effectiveness of fexofenadine hydrochloride 30 mg twice daily for the treatment of seasonal allergic rhinitis in patients 2 to 5 years of age is based on the pharmacokinetic comparisons in adult and pediatric subjects and an extrapolation of the demonstrated efficacy of fexofenadine hydrochloride in adult subjects with this condition and the likelihood that the disease course, pathophysiology, and the drug's effect are substantially similar in pediatric patients to those in adult patients. The effectiveness of fexofenadine hydrochloride for the treatment of chronic idiopathic urticaria in patients 6 months to 11 years of age is based on the pharmacokinetic comparisons in adults and children and an extrapolation of the demonstrated efficacy of fexofenadine hydrochloride in adults with this condition and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar in children to that of adult patients. Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.
Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
INTRODUCTION: Neuromyelitis Optica Spectrum Disorders (NMOSD) is a neuroinflammatory condition characterized by optic neuritis and transverse myelitis. While the current approach to NMOSD focuses on relapse-associated worsening (RAW), recent evidence indicates Relapse-Independent Disease Activity (RIDA) in patients.
METHOD: Databases including Embase, PubMed, Scopus, and Web of Sciences were systematically searched up to December 2023. No restrictions were applied. Inclusion criteria focused on studies reporting evidence of RIDA in NMOSD patients. Data extraction involved details such as study title, author, participant characteristics, treatment, evaluation methods, positive findings according to RIDA, and prevalence of findings in NMOSD patients. This study is conducted following the PRISMA guidelines with a registered protocol on PROSPERO (ID = CRD42023492352).
RESULT: Of 802 studies, 38 were included in the systematic review, covering 1881 NMOSD patients. AQP4-IGg status was positive in 90.6 % of the patients. Ocular findings indicative of RIDA were reported in 23 studies, including thinning of GCIPL, RNFL, GCC, and GCL layers, foveal and macular shape and volume abnormalities, vessel loss, and visual evoked potentials (VEPs) abnormalities. MRI findings supporting the RIDA were reported in 13 studies, including new lesion incidence and brain and spinal cord atrophy. Serum and CSF RIDA-supporting findings were reported in five studies, including elevation in sGFAP and sNFL. Biopsies and autopsies suggested inflammatory processes in relapse-free patients in 2 studies. The predominant manifestation of RIDA in NMOSD was identified in the visual system, suggesting the impaired retinal glial cells like Müller cells during the relapse-free period in NMOSD.
INTERPRETATION: Our systematic review provides valuable insights into RIDA in NMOSD. Establishing guidelines for the diagnosis and treatment of RIDA is crucial. Further studies are needed to provide robust evidence on RIDA in NMOSD patients.
The invention relates to glycosaminoglycan lyase difficult to degrade CS-E, and a coding gene and application thereof. The amino acid sequence of the glycosaminoglycan lyase is shown as SEQ ID NO. 2; the coding gene and the nucleotide sequence of the glycosaminoglycan lyase are shown in SEQ ID NO. 1; the specific activities of the glycosaminoglycan lyase prepared by the invention on HA and CS-A, CS-C, CS-D, CS-E are respectively 13.8, 7.2, 6.7, 5.9 and 5.3U/mg. And the low sulfated CS-E polysaccharide is used as a substrate to prepare the high sulfated oligosaccharide with different polymerization degrees, and the prepared high sulfated oligosaccharide can be used for resisting tumor metastasis. The enzyme can also be applied to the fields of medicines, cosmetics and the like, and has wide application prospect.
Participants ≤3 years of age with an undetermined MPS II phenotype. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
The invention relates to bioengineering, and the foods and pharmaceutical industries. The composition for normalizing microflora and purifying an organism from toxins comprises at least one insoluble enterosorbent, at least one prebiotic, and at least one edible fat or oil of the lauric type with a melting point of no higher than 39°С, with a particle size of no greater than 65 µm, with the following content of components in mass%: enterosorbent 3-47%; prebiotic 3-47%, edible fat or oil of lauric type 15-55%, with a moisture content in the composition of no greater than 1%. The insoluble enterosorbent is in the form of insoluble dietary fibres or a mineral substance. The prebiotic is in the form of an oligosaccharide. The edible fat or oil of lauric type is selected from the following group: lauric-type cocoa butter substitutes, coconut oil, and palm oil. The method for detoxification and sanitation of an organism consists in that the enterosorbent as well as the prebiotic and the fat or oil of lauric type are added to food simultaneously at least twice a day over the course of 2-3 weeks. The composition is administered perorally in a quantity of 50-250 g a day.
BACKGROUND AND AIMS: The mineral compound Luvos Healing Earth (LHE) is a commercially available remedy empirically used for a variety of gastrointestinal disorders. The aim of this study was to investigate the possible effect of prolonged LHE therapy on gut microbiota in healthy individuals and in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
METHODS: In this prospective exploratory study, a total of 20 participants, including 12 healthy controls and 8 patients with IBS-D, received treatment with LHE (Magenfein Granulat, 1 sachet bid) for 6 weeks. Fecal samples were collected for microbiota analysis in the morning fasting state at regular intervals at 6 different timepoints: 2 weeks before starting therapy (Screen), and every 2 weeks during LHE therapy (V0-V3). Additionally, a follow-up visit was scheduled 4 weeks after the end of treatment (V4). Microbiota analysis was performed using the GA-map® Dysbiosis Test Lx v2. Dysbiosis Index, bacterial diversity, as well as the balance or imbalance of functionally important bacteria were assessed.
RESULTS: The microbiota analysis revealed an overlap in gut microbiota profiles between healthy controls and patients with IBS-D. Bacterial communities were consistently stable during the entire treatment period, and no significant variations in composition were observed 4 weeks after the end of the therapeutic intervention. There was a remarkable stability of microbiota profiles over time within each individual and a high inter-individual variation. The majority of fecal samples exhibited profiles, reflecting an eubiotic state, with no significant changes in dysbiosis index, functional bacteria profiles, or bacterial diversity.
CONCLUSION: Our findings indicate intraindividual resilience of microbiota consortia during the entire study period. Prolonged intake of LHE does not cause significant alterations in fecal microbiota profiles in healthy controls and patients with IBS-D. Luvos Healing Earth does not affect the stability of gut microbial diversity and bacterial functions.
Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but has not been explored in Veterans with ongoing mental health issues and has not been compared to an active treatment.
Non-ventilated hospital-acquired pneumonia (NV-HAP) is associated with a significant healthcare burden, arising from high incidence and associated morbidity and mortality. However, accurate identification of cases remains challenging. At present, there is no gold-standard test for the diagnosis of NV-HAP, requiring instead the blending of non-specific signs and investigations. Causative organisms are only identified in a minority of cases. This has significant implications for surveillance, patient outcomes and antimicrobial stewardship. Much of the existing research in HAP has been conducted among ventilated patients. The paucity of dedicated NV-HAP research means that conclusions regarding diagnostic methods, pathology and interventions must largely be extrapolated from work in other settings. Progress is also limited by the lack of a widely agreed definition for NV-HAP. The diagnosis of NV-HAP has large scope for improvement. Consensus regarding a case definition will allow meaningful research to improve understanding of its aetiology and the heterogeneity of outcomes experienced by patients. There is potential to optimize the role of imaging and to incorporate novel techniques to identify likely causative pathogens. This would facilitate both antimicrobial stewardship and surveillance of an important healthcare-associated infection. This narrative review considers the utility of existing methods to diagnose NV-HAP, with a focus on the significance and challenge of identifying pathogens. It discusses the limitations in current techniques, and explores the potential of emergent molecular techniques to improve microbiological diagnosis and outcomes for patients.
PCT No. PCT/EP95/05149 Sec. 371 Date Sep. 4, 1997 Sec. 102(e) Date Sep. 4, 1997 PCT Filed Dec. 27, 1995 PCT Pub. No. WO97/07685 PCT Pub. Date Mar. 6, 1997The invention relates to a process for producing a preparation containing the polyphenols of green tea (Thea chinensis) in readily available, unoxidised form, in which fresh green tea leaves are cooled until the activity of the phenol oxidases therein has dropped to at most 1% of the value at normal temperature and at the same time or immediately afterwards the water acting as the reaction medium is removed. Products made by this process are packed in capsules soluble in hot water.
The present invention relates to method of identifying gene sequences of potential vaccine antigens. Also included are gene sequences and the polypeptides encoded by the gene sequences as well as the use of such sequences to induce a protective immune response in animals. Particularly, the invention relates to identifying potential antigen gene sequences of mycoplasma, preferably mycoplasma hyopneumoniae. In one aspect of the present invention there is provided a method of identifying expression proteins translated from a nucleotide sequence in an expression vector, said method comprising the use of a marker co-expressed with a protein translated from the nucleotide sequence. In a further aspect of the present invention there is provided a method of identifying a therapeutic antigenic gene sequence encoding a therapeutic antigenic protein of a disease, from a sample of nucleotide sequences. Preferably the marker is a polyHis tag.
Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
A cosmetic composition containing a lipid capsule having ultraviolet absorber and protector is provided to improve the stability to the heat and light of the composition and suppress the coagulation of the particle. A cosmetic composition comprises a lipid capsule having an ultraviolet absorber or protector. The diameter of the lipid capsule is 10nm-5mm. The ultraviolet absorber is a cinnamater derivative containing octyl methoxycinnamate and isoamyl-p-methoxycinnamate, salicylic acid derivative containing butylmethoxy dibenzoylmethane, bis-ethylhexyloxyl phenolmethoxy phenyl triazine, and octyl salicylate, and benzophenones. The ultraviolet protector is ZnO (zinc oxide), TiO2 (titanium dioxide), silicate or talc. The lipid which is used in producing the lipid capsule is a higher alcohol containing behenyl alcohol, cetyl alcohol, stearyl alcohol, glyceryl monostearate, cetostearylalcohol, and bathyl alcohol, fatty acid containing stearic acid, palmitic acid, and myristic acid, and lipid peptide containing lecithin, and cerebroside.